Related Experiment Video
Updated: Aug 26, 2026
Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
Cardiac allograft vasculopathy
1Methodist Specialty and Transplant Hospital, San Antonio, TX 78229, USA. lanaboomersooner@sbcglobal.net
Insights
Cardiac allograft vasculopathy (CAV) is a major cause of death after heart transplantation. This accelerated coronary artery disease in recipients currently has retransplantation as its only definitive treatment.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Heart transplantation is a standard treatment for end-stage heart disease.
- Cardiac allograft vasculopathy (CAV) is a significant complication, leading to death in over half of heart transplant recipients within a year.
- CAV is characterized by accelerated obliterative coronary artery disease in the transplanted heart.
Purpose of the Study:
- To review the pathogenesis, characteristics, and treatment options for cardiac allograft vasculopathy (CAV) in heart transplant recipients.
- To highlight the challenges associated with managing CAV and its impact on long-term transplant outcomes.
Main Methods:
- Literature review of pathogenesis, clinical characteristics, and treatment modalities for CAV.
- Discussion of current therapeutic strategies and future directions.
Main Results:
- CAV represents an accelerated form of coronary artery disease unique to heart transplant recipients.
- Retransplantation is currently the only definitive treatment for CAV.
- Significant obstacles, including ethical considerations and donor organ scarcity, limit the feasibility of retransplantation.
Conclusions:
- CAV remains the primary cause of late mortality following heart transplantation.
- Effective management strategies for CAV are urgently needed to improve long-term survival and outcomes for heart transplant recipients.
- Addressing the challenges of retransplantation is crucial for improving the prognosis of patients with CAV.
Abstract:
The purpose of this article is to discuss the pathogenesis, characteristics, and treatment modalities for heart transplant recipients with cardiac allograft vasculopathy (CAV). Cardiac transplantation has become an acceptable mainstream treatment for end-stage cardiac disease. Unfortunately, CAV is the leading cause of death after the first year of transplant. CAV is an accelerated form of obliterative coronary artery disease that occurs in the heart transplant recipient. Currently, retransplantation is the only definitive treatment. Ethical concerns and the shortage of donor organs present a huge obstacle to retransplantation and the long-term outcome of heart transplant recipients.
